Lightstone Ventures related stories
All articles and analysis
Roche to buy VC-backed biotech firm PromediorRoche has agreed to acquire Lexington, Massachusetts-based Promedior, a biotech company. According to terms of the agreement, Roche will make an upfront cash payment of $390 million. Promedior's backers include Morgenthaler Ventures, HealthCare Ventures, Forbion, Easton Capital, Fibrotec Ventures and Polaris Partners.
- Cyteir Therapeutics scores $40.2 mln Series B
Lexington, Massachusetts-based Cyteir Therapeutics, a developer of next-generation synthetic lethal therapies for cancer, has secured $40.2 million in Series B funding. Novo Holdings led the round with participation from Venrock, DROIA Oncology Ventures, Osage University Partners, Lightstone Ventures and Celgene Corporation. As part of this closing, Dr. Karen Hong of Novo Ventures will join the Cyteir board.
- Locana snags $55 mln Series A
San Diego-based Locana Inc, a RNA-targeting gene therapy company, has raised $55 million in Series A financing. ARCH Venture Partners led the round with participation from other investors that included Temasek, Lightstone Ventures, UCB Ventures and GV.
- Locana snags $55 mln Series A
San Diego-based Locana Inc, a RNA-targeting gene therapy company, has raised $55 million in Series A financing. ARCH Venture Partners led the round with participation from other investors that included Temasek, Lightstone Ventures, UCB Ventures and GV.
- Cala Health nabs $50 mln Series C
Burlingame, California-based Cala Health, Inc, a bioelectronic medicine company, has raised $50 million in Series C financing. The investors included Novartis, Baird Capital, LifeSci Venture Partners, TriVentures, Johnson & Johnson Innovation – JJDC, Inc, Lux Capital, Lightstone Ventures, Action Potential Venture Capital, dRx Capital and GV.
- Nuvaira nets $79 mln in USVP-led round
Minneapolis-based Nuvaira, a developer of medical devices that treat obstructive lung diseases, has raised $79 million in financing. U.S. Venture Partners led the round with participation from other investors that included Endeavour Vision, Qiming Venture Partners, Lightstone Ventures, Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners, Versant Ventures, Vertex Venture Holdings and Windham Venture Partners.
- Biotech company Nimbus Therapeutics garners $65 mln
Cambridge, Massachusetts-based Nimbus Therapeutics, a biotechnology company, has secured $65 million in funding. The investors included Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, Lightstone Ventures and Schrödinger.
- Escient Pharmaceuticals rakes in $40 mln Series A
San Diego-based Escient Pharmaceutials, a newly launched biotech company, has closed $40 million in Series A funding. The investors were The Column Group, 5AM Ventures and Osage University Partners.
- Cyteir Therapeutics rakes in $29 mln Series B
Cambridge, Massachusetts-based Cyteir Therapeutics, a developer of synthetic lethal therapies that treat cancer and autoimmune disease, has raised $29 million in Series B financing. Venrock led the round with participation from other investors that included Celgene, Lightstone Ventures and DROIA Oncology Ventures.